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E-mail address: paul.garside@glasgow.ac.uk (P. GaDespite the profound impact of biologics on the treatment of rheumatoid arthritis (RA), long lasting
disease remission remains elusive. We propose that this is a consequence of failing to target the
right molecular pathway in the most relevant patient group at the appropriate time and place in dis-
ease progression. A limitation to testing this approach is the availability of disease models repre-
senting the discrete steps in autoimmune pathogenesis. A particular example is the paucity of
models to dissect the conditions permissive for the breach of self-tolerance, which would subse-
quently allow identiﬁcation and testing of therapeutics for re-establishment of self-tolerance. We
conclude that a detailed understanding of the location and timing of events leading to the systemic
breach of self-tolerance and subsequent progression to tissue speciﬁc pathology are required if
rational application of existing drugs and identiﬁcation of novel targets is to be achieved. This will
take the personalised medicine revolution into the realms of contextualised medicine, whereby the
right drug is targeted to the right tissue, in the right patient, at the right time.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Rheumatoid arthritis (RA) is a chronic, inﬂammatory autoim-
mune disorder whereby the immune system promotes articular
damage. It is a disabling and painful condition, which can lead to
severe loss of mobility due to pain and joint destruction. RA is a
systemic disease, often affecting extra-articular tissues throughout
the body including the skin, heart, lungs, and muscles [1–5]. With
approximately 50% of RA patients are unable to work 10 years after
the onset of their disease [6] and recent studies showing 0.44% of
men and 1.16% of women in the UK population suffering from RA
[7] and increased mortality in these patients [8], accurate diagnosis
and monitoring of the condition is critical. The processes that ini-
tiate and perpetuate RA are currently unclear and consequently
the pursuit of novel therapies for RA has been mostly empirical.
However, over the last 15 years improvements in molecular biol-
ogy and biochemistry, together with improved understanding of
cytokine biology, have identiﬁed molecules such as TNF as playing
a central role in RA pathogenesis. These studies were greatly facil-
itated by the availability of ex vivo synovial membranes from the
clinic as well as the availability of an animal model, collagen in-
duced arthritis (CIA), for in vivo studies. As a direct result of
improving our understanding of the basic biological/pathological
mechanisms involved in RA we have continued to identify andcal Societies. Published by Elsevier
rside).validate new therapeutic strategies. Subsequent to TNF blockade,
targeting IL-6 is in advanced clinical development and additional
cytokine targets such as IL-17 and IL-15 [9–12] appear promising.
While these treatments have revolutionised the treatment of RA,
some patients remain refractory to biologic intervention [13]. Thus,
while the control of inﬂammation has been mainly successful, the
critical objective in rheumatoid therapeutics is now to re-establish
peripheral tolerance and thereby maintain therapeutic remission.
If achieved, this could bring about therapeutic induction of drug
free remission. The advent of anti-CD20 (rituximab; potentially
modifying B cell APC function) and of CTLA4-Ig in RA suggests that
such effects may be achievable, although these approaches are not
optimal [14]. In particular, these strategies result in non-speciﬁc
effects on immune function, potentially leading to suppression of
beneﬁcial immune function such as those pertaining to defence
against infectious agents and neoplasms. Our incomplete under-
standing of the mechanisms of breach of self-tolerance has criti-
cally impaired the development of such novel therapeutics.
Speciﬁcally, there is a need for models and approaches that allow
detailed analysis of the processes that regulate tolerance in arthri-
tis in vivo. Such models should facilitate identiﬁcation of the major
cellular and molecular interactions involved in RA pathogenesis
and analysis of their integration prior, and subsequent, to breach
of self-tolerance to gain insights into the steps required to re-
educate the immune system. In this instance, early clinical inter-
vention is likely to be essential if a patient’s immune system is
to be re-programmed. While approaches such as the case controlB.V. Open access under CC BY-NC-ND license.
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variations associated with the development of RA, they will not
inform when and where to intervene for a given pathway. Under-
standing the events surrounding the breach of self-tolerance asso-
ciated with RA could therefore reveal markers associated with the
onset of preclinical disease and signal a window of early interven-
tion that would prevent the initiation of the cascade of events lead-
ing to symptomatic disease.
2. What is tolerance and breach of tolerance?
Tolerance is deﬁned as a state of antigen speciﬁc unresponsive-
ness to subsequent exposure to that antigen in an immunogenic
form in an otherwise immunocompetent organism. This usually
comprises components of central and peripheral tolerance. Specif-
ically, central tolerance, mediated by mechanisms such as clonal
deletion and/or anergy, is established during the education of
developing T and B cells. Peripheral tolerance exists to regulate
responses that were not centrally tolerised (due to lack of exposure
to these in primary lymphoid organs) or are peripherally breached
(for general reviews of central and peripheral tolerance see Refs.
[16–20]). Proposed mechanisms include deletion, anergy, igno-
rance and active regulation. Dysregulation of either central or
peripheral tolerance has been associated with the development
of autoimmunity in both animal models and patient studies
[21–27].
Disease models have contributed signiﬁcantly to a detailed
mechanistic understanding of human autoimmune disease in gen-
eral. Unlike many other conditions, animal models of RA have
tended to focus on the later stages of disease pathogenesis. How-
ever, recent clinical studies demonstrating the predictive utility
of anti-citrullinated protein/peptide antibodies (ACPA) for subse-
quent development of RA reveal that the most critical checkpoint,
breach of self-tolerance, occurs months or years prior to clinical
presentation [28–30]. This is the least well studied or understood
aspect of the disease, due to the limitations of existing rodent mod-
els to dissect events surrounding the induction of autoimmunity.
For example, the majority of animal studies employ powerful,
non-physiological adjuvants or a large number of self-reactive
TCR transgenic cells to drive breach of tolerance to exogenously
administered self-antigens [31–35]. Therefore, little is known
about the immunological processes that lead to the spontaneous
loss of tolerance that is characteristic of human disease. This repre-
sents a bottleneck to the clinical development of prevention and
early intervention strategies.
3. Factors involved in breach of self-tolerance
A critical role for adaptive immunity in the pathogenesis of RA
is supported by the presence of activated T cells in the synovial le-
sion, by long established association with HLADR04 and by recent
genome wide scanning studies implicating ptpn22, cd40, ctla4
and cd28 [36–38]. Deﬁnitive proof of concept for adaptive immuneTable 1
Environmental factors and RA.
Environmental factor Effect
Smoking Increased risk, dependent on magnitude and length of
Alcohol May decrease risk, lower risk for anti-CCP positive RA
High birth weight Increased risk
Oral contraceptives Lowers the risk of RF positivity
Breast feeding Reduced risk
Socioeconomic status Inverse association between socioeconomic status, mea
Geography Location of birth and current residence is associated w
Microbiota Intestinal ﬂora could be protective, P. gingivalis promotinvolvement resides in the proven efﬁcacy of therapeutics such as
rituximab and abatacept, targeting B and T lymphocytes, respec-
tively [39,40]. The conglomeration of genetic and environmental
factors promoting breach of self-tolerance, autoimmunity and pro-
gression to pathology are legion, yet our understanding of their
integration is limited (see summary in Table 1).
3.1. Genetics
The description of the Human Leukocyte Antigen (HLA) associ-
ation with RA is the strongest evidence for the genetic basis of dis-
ease [41]. Most patients with RA express particular HLA-DR alleles
such as HLA-DRB1⁄0401, ⁄0404, ⁄0405, ⁄0408, ⁄0101, ⁄0102, ⁄1001
and ⁄1402 [42]. RA associated HLA-DR alleles share a highly con-
served amino acid motif (70QRRAA74, 70RRRAA74 or 70QKRAA74)
expressed in the third hypervariable region of the DRB1 chain,
termed the shared epitope (SE) [42]. Apart from MHC, the best
established locus of susceptibility for RA is protein tyrosine
phosphatase non-receptor type 22 (PTPN22) which encodes Lyp,
a tyrosine phosphatase known to be a powerful inhibitor of T cell
activation [22]. The minor allele of a single nucleotide polymor-
phism (SNP) in PTPN22 has been linked to autoimmunity [24]. This
SNP has been suggested to result in a gain of function, increasing
the T cell activation threshold, which leads to a failure of thymic
negative selection. Genome wide association studies (GWAS) have
conﬁrmed the association of HLA-DR1 and PTPN22 with RA [25].
Other candidate genes are CTLA-4, the a and b chain of the IL-2
receptor (IL-2RA and IL-2RB), genes of the TNF pathway (TNFAIP2
(tumour necrosis factor, alpha-induced protein)) and in the regula-
tion of T-cell function by granzyme B (GZMB) [25].
3.2. Environment
The amount of data relating to environmental factors that con-
tribute to the development of the disease is surprisingly scarce.
Smoking is the environmental factor most strongly linked to an
increased risk of developing RA [43–47]. A link has been demon-
strated between the HLA-DRB1 shared epitope (SE), citrullination
and smoking [48,49]. Antibodies to antigens modiﬁed by citrullina-
tion, through deamination of arginine to citrulline (anti-cyclin
citrullinated peptide (anti-CCP) antibodies), are present in approx-
imately two-thirds of RA patients but are rare in other inﬂamma-
tory conditions [12]. It has been proposed that smoking triggers
citrullination by activation of peptidylarginine diaminase (PAD)
[49] in alveolar antigen presenting cells (APCs), enabling efﬁcient
antigen presentation of the post-translationally modiﬁed peptides
for which the immune system has not developed tolerance [44,50].
In addition, it has been reported that the conversion of arginine to
citrulline at the peptide side-chain position interacting with the SE
signiﬁcantly increases peptide-MHC afﬁnity, which could lead to
an immune response in individuals carrying the susceptible HLA-
DRB1 alleles [51]. Recently great attention has been given to the
immunomodulatory role of mucosal microﬂora [52,53]. Interest-References
habit, association with anti-CCP antibodies [43,45,46,48,50,156]
[156,157]
[158]
[159]
[160]
sured by occupational class and education and RA [161]
ith differential risk of RA [162]
es disease [52–55]
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than non-RA patients [54]. It has been proposed that normal
intestinal microﬂora may protect against the development of
inﬂammatory diseases [53,55,56]. Mice deﬁcient in a G-protein
coupled receptor that recognises products of ﬁbre metabolism by
gut microbes developed exacerbated arthritis in the KxB/N ser-
um-induced arthritis model, which suggests that commensal bac-
teria might be required for regulation of the immune response.
Other reports suggest that components of the microﬂora drive
arthritis development [57,58]. A prime example of a possible link
between the mucosal microﬂora and RA pathogenesis is Porphyro-
monas gingivalis. P. gingivalis has been linked to the development of
immunity against citrullinated proteins due to its ability to pro-
duce citrullinated epitopes [59–62] and its presence in an environ-
ment highly analogous to RA, characterised by bone erosion and
chronic inﬂammation.
4. Establishment of breach of self-tolerance and autoimmunity
Though adaptive immunity appears to be a central component
of RA pathogenesis, clearly a variety of cell types contribute to dis-
ease. For example, it has recently been proposed that the progres-
sion to pathology in RA is a four-step process, which does not
require antigen-speciﬁc recognition events. These four steps have
been proposed as (i) T cell activation regardless of antigen speciﬁc-
ity, (ii) local events inducing tissue-speciﬁc accumulation of acti-
vated T cells, (iii) enhanced sensitivity to T cell-derived cytokines
in populations of cells in affected tissue, and (iv) activation of a
cytokine-dependent IL-6 ampliﬁcation loop, ‘‘IL-6 ampliﬁer’’,
triggered by CD4+ T cell-derived cytokines such as IL-17A [63].
However, to some extent this is a question of semantics, as there
is considerable evidence to support not only roles for non-immune
components, but also innate and adaptive immunity and
importantly, their integration as summarised in Fig. 1 and detailed
below.Fig. 1. Pathogenesis of rheumatoid arthritis? Summary of potential factors involved
pathogenesis, highlighting uncertainty regarding the mechanisms underlying transition5. Non-immune cells
It is becoming increasingly clear that cells not conventionally
considered immune cells have signiﬁcant impact on the organisa-
tion, localisation and function of the immune system.
5.1. Osteoclasts
Osteoclasts are multinucleated cells of haemopoeitic origin, the
primary bone reabsorbing cells, and are essential for the remodel-
ling of bone throughout life [64]. These giant cells contain up to 20
nuclei [65] and only a few clinical conditions induce their local for-
mation, one of these being RA. Synovial inﬂammation can drive
osteoclastogenesis [65,66]; the synovial membrane contains many
monocytes/macrophages that can undergo osteoclast differentia-
tion under the appropriate conditions. Cell types considered very
important in providing differentiation signals for monocytes to
become osteoclasts are ﬁbroblasts and T cells. Fibroblasts are the
cells of the pannus, a major component of the hyperplastic synovial
membrane and express receptor activator of nuclear factor jB
(NFjB) ligand (RANKL), which is a major driver of osteoclast
formation [67]. T lymphocytes, apart from RANKL, express cyto-
kines such as IL-17 that support osteoclast formation [68]. Other
cytokines present in the synovial environment such as TNF, IL-1
and IL-6 also are important in RANKL upregulation and possibly
on osteoclast formation [65]. From models of arthritis it is evident
that osteoclast formation is an early and rapid pathological event
[69], which eventually leads to the destruction of the joint.
5.2. Synovial ﬁbroblasts
Synovial ﬁbroblasts, together with synovial macrophages, are
the main cellular components of the synovial membrane. RA syno-
vial ﬁbroblasts are now considered active drivers of RA pathology
[70]. The physiological function of these cells is to provide the jointin inﬂammatory arthritis, how they may integrate at different stages of disease
from the prearticular to acute pathology state.
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cules such as hyaluronic acid. Human synovial ﬁbroblasts contrib-
ute to disease pathology through the production of inﬂammatory
mediators and chemokines, such as VEGF, IL-15, interferon-b
(IFNb), IL-8, CXCL2, CCL8, CCL5, CXCL10 [71–74] and degradative
enzymes, notably cathepsins and matrix metalloproteases [75–
77]. It should be noted that RA synovial ﬁbroblasts differ consider-
ably from healthy joint ﬁbroblasts. RA ﬁbroblasts have an activated
phenotype, which is characterised by morphological differences,
long-term growth, reduced apoptosis and an altered response to
various stimuli. A recent study demonstrated that RA ﬁbroblasts
were able to spread pathology by invading unaffected joints, an
ability lacking in non-RA ﬁbroblasts [78]. Various mechanisms
could be involved in the development of this phenotype, amongst
them cytokines and growth factors (FGF, IL-17, IL-18, TNF and IL-1)
[70,79–82], articular hypoxia of the rheumatoid joint activating the
production of pro-angiogenic and pro-inﬂammatory factors [83],
and expression of proto-oncogenes and tumour suppressors [84].
6. Innate immune cells
6.1. Monocytes/macrophages
The predominance of macrophage-derived cytokines in the
synovial compartment signiﬁes the importance of this cell type
in the pathology of RA. In the normal synovial membrane, macro-
phages predominate in the lining where they scavenge debris from
articular structures and eliminate all microorganisms entering via
the blood or following trauma [85]. In the inﬂamed synovial mem-
brane activated macrophages are one of the most abundant cell
types [85] and the degree of macrophage inﬁltration directly corre-
lates with clinical status and progression of joint damage [86,87].
At the tissue level, pre-activated monocytes inﬁltrate the synovial
membrane, mature into macrophages, which are activated and
interact with other synovial cells [88]. Activated macrophages con-
tribute to the progression of pathology through production of a
panoply of mediators such as pro-inﬂammatory cytokines (e.g.,
TNF-a, IL-1, IL-6 and GM-CSF), chemoattractants and chemokines
(e.g., IL-8, MCP-1 and MIP-1) and matrix metalloproteinases (e.g.,
MMP9 and MMP12) which may all contribute to tissue destruction
[48]. Clearly, macrophages may also play a role in antigen presen-
tation, though it appears that the major player in this function to
link innate and adaptive immunity is the dendritic cell (DC).
6.2. Dendritic cells
DCs comprise a complicated population of heterogeneous APCs
that are critical for the initiation of the adaptive immune response
and the maintenance of both central and peripheral tolerance [89].
DCs in both human and mice can be divided into subsets according
to tissue distribution, function and phenotype [90]. DCs have been
identiﬁed in RA synovial ﬂuid and synovial tissue by several groups
but their origin, function and potential role in the pathogenesis are
not fully understood [91,51]. A major subdivision can be made be-
tween conventional and plasmacytoid DCs (cDCs and pDCs, respec-
tively) [90]. Contrary to other APCs, DCs can prime naïve T cells for
helper and cytotoxic functions, are essential for the generation of
primary antibody responses, and are powerful enhancers of natural
killer cells [92]. DCs can potentially play a number of roles in the
pathogenesis of RA. Firstly, DCs could prime autoimmune re-
sponses by presenting self-antigens. Our group has demonstrated
that the presentation of collagen derived peptides by mature bone
marrow derived DCs is sufﬁcient to induce arthritis in DBA/1 mice
[93]. More importantly, in a model of pre-clinical arthritis, we have
demonstrated that conventional DCs are the cells that orchestratethe initial breach of self-tolerance [94]. Secondly, DCs could inﬁl-
trate the synovial tissue and ﬂuid where they could take up and
present antigen locally, perpetuating the disease, however there
are no direct evidence to support this [95]. Furthermore, DCs,
alongside with other immune cells and synoviocytes produce
inﬂammatory mediators that drive RA pathology [96].
DCs are critical for peripheral and central tolerance. Both cDCs
and pDCs have been suggested to have tolerogenic abilities in dif-
ferent environmental settings. We have previously demonstrated,
using a breach of self-tolerance model in the context of arthritis,
that pDCs can function to limit self-reactivity and the consequent
pathology [96]. To further support a regulatory role for pDCs a tol-
erogenic CCR9+ pDC population, which can suppress acute host
versus graft disease, has been also demonstrated [97]. Even though
there is an incomplete understanding of how DCs are involved in
RA pathology, DCs therapies are currently under development with
some success in murine models [98–100], whereas clinical trials
have been initiated in UK (http://www.news.bbc.co.uk/1/hi/
health/7560535.stm) and Australia (http://www.uq.edu.au/news/
?article=13128). It should also be noted that the success/or not of
DC therapeutics will no doubt rely on important spatiotemporal
information, i.e., do the DCs need to be targeted to the secondary
lymphoid tissues or somatic tissue, and how effective this ap-
proach is at different stages of disease progression?
7. Adaptive immune cells
7.1. B cells
A critical role for B cells in RA pathogenesis is now supported by
the clear association of particular autoantibody speciﬁcities, eleva-
tion of B cell survival factors (e.g., APRIL, BAFF and IL-21) and al-
tered circulating B cell subpopulations [101,102], with
progression to disease and the therapeutic effectiveness of B cell
depletion. More circumstantial evidence includes the localisation
of B cells and their activation and formation of ectopic germinal
centres in RA synovial membranes. The ﬁrst reported contribution
of B cells, helped by the accessibility of peripheral blood, was the
identiﬁcation of rheumatoid factor (RF), an autoantibody against
the Fc portion of human IgG. RF is found in about 80% of RA pa-
tients but it is not speciﬁc to RA and can be found in other autoim-
mune conditions and even in 10% of healthy individuals [1]. There
are differences between RF in health and disease. In healthy indi-
viduals, the RF isotype is IgM and is produced by B1 cells as ‘‘nat-
ural’’ antibody with low afﬁnity and polyreactivity. In contrast, in
RA patients, RF has undergone afﬁnity maturation and class
switching [103]. The association of cognate T cell/B cell interac-
tions with disease is further highlighted by the diagnostic value
of class switched anti-CCP antibodies [104]. B cell inﬁltration is less
prominent in samples of synovial tissue that lack a deﬁned level of
organisation of immune cells, whereas they are more signiﬁcant in
samples characterised by large and well organised mononuclear
aggregates [105]. In synovial membranes, B cells are the major
source of lymphotoxin-B (LT-b), an important cytokine in normal
lymphoid organogenesis [106] suggesting a signiﬁcant role of B
cells in ectopic lymphoid tissue organisation. A deﬁned lymphoid
architecture in synovial tissue, with B cells in close proximity to
T cells, provides the appropriate microenvironment for B cell acti-
vation. In addition, increased B cell activation markers, such as Blys
and APRIL, have been reported in RA synovial membrane [107]. B
cells can act as efﬁcient APCs in an antigen speciﬁc manner to stim-
ulate T cells and to allow optimal CD4+ T cell memory. RF+ B cells
can take up antigen-IgG immune complexes via their membrane Ig
receptors, which are IgG speciﬁc. B cells then process and present
peptides from the antigen and provide T cell activation and help,
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cells are also a source of various cytokines, most importantly IL-6,
TNF and LT, following BCR ligation and CD40 activation [109].
These cytokines have a profound autocrine impact on B cell activity
and differentiation, and serve to amplify the ongoing immune re-
sponse. As noted above, the importance of B cells in RA pathology
is deﬁned by the effectiveness of B cell depletion therapies. Ritux-
imab is a potent CD20-speciﬁc monoclonal antibody, which can kill
B cells from the pre-B-cell stage to the pre-plasma-cell stage [110].
Several B cell depletion agents are now under investigation with
the re-establishment of immunological tolerance as a major goal.
7.2. T cells
The evidence for T cell involvement in RA include the associa-
tion of HLA-DR4 and HLA-DR1 alleles, the effects of T cell derived
cytokines, T-cell dependent experimental models of arthritis, and
the anti-arthritic effects of T-cell directed therapies. Numerous
animal models conﬁrm the genetic evidence for T-cell involvement
in RA. An intrinsic defect in TcR signalling, where a spontaneous
point mutation alters the encoding of an SH-2 domain of ZAP70,
can lead to T-cell dependent arthritis in mice [21]. On the other
hand, immunization with glucose-6-phosphate isomerase induces
T-cell dependent polyarthritis in DBA/1 mice [111]. We have devel-
oped a model of breach of self-tolerance, where a Th1 response to
irrelevant antigen (OVA) results in arthropathy associated with
spontaneous induction of autoreactive T and B cell responses
[112]. Recent studies suggest that a new subset of effector T-cells
distinct from T helper (Th) 1 and Th2 subsets, producing IL-17
and termed Th17, characterises the pathology of rheumatoid
arthritis in animal models at least. The contribution of an addi-
tional T cell subset (Treg) must also be considered, where the bal-
ance of active regulation by FoxP3+ regulatory T cells and
pathogenic Th subsets impact on disease progression [113]. T cells
have also been detected in RA synovial membrane and are mainly
activated memory CD4+ CD45RO+ cells [114]. In patients with RA
and ankylosing spondylitis, IL-17+ and IL-22+ CD4+ T cells could
be detected in the circulation and were increased compared to
healthy controls [115]. Development of this Th17 responses is
likely to occur early in disease pathogenesis, with dysregulated
Th17 related cytokine production evident in VERA (very early RA)
patients [116]. Various T-cell directed therapies have been devel-
oped with the greatest success being abatacept, a fully human re-
combinant fusion protein consisting of the extracellular domain of
endogenous inhibitory molecule cytotoxic T-lymphocyte antigen 4
(CTLA-4) and the Fc domain of human IgG1 [114].
8. Cellular interactions in RA
The interactions between the cell types noted above need to be
choreographed to elicit an adaptive immune response. The induc-
tion of an adaptive immune response begins when an antigen is in-
gested by immature DCs in the presence of pathogen associated
molecular patterns (PAMPS) or danger associated molecular pat-
terns (DAMPS) [117–119]. The activated DC are carried away from
the involved tissue in lymph, along with their antigen cargo, to
enter peripheral lymphoid tissue in which they can interact with
naïve T cells and initiate the adaptive immune response
[119,120]. Activated DCs will interact with antigen speciﬁc T cells,
which in response will proliferate and differentiate into effector Th
cells [119,121–123]. We hypothesise that these events are identi-
cal or similar in autoimmunity, but why they are dysregulated to
allow responses to self-antigens remains unclear. In both of these
situations our current knowledge has depended on static analysis
of cells in/from ﬁxed tissues. The important subtleties of the dy-namic and localised nature of cellular interactions of the immune
system deep within tissues have only become tractable following
recent technological developments, and this allows us to answer
critically important questions. Obviously movement and interac-
tion of the components of the immune system occur in specialised
compartments in vivo, however it is clear that these interactions
are also highly dynamic. For example, studies using intravital-
multiphoton microscopy have demonstrated that the movement
behaviour of T cells in intact lymph nodes, following primary and
secondary exposure to immunogenic or tolerogenic forms of anti-
gen, are quantitatively different [124,125]. More recent studies
have also begun to conﬁrm the long suspected importance of im-
mune surveillance and reveal the underlying molecular mecha-
nisms involved in this process. These studies also highlight the
importance of scale within the immune system, as migration and
localisation are important at levels from cell through organ to
organism. At one end of the scale, the requirement for T cell migra-
tion into B cell follicles for the evolution of a productive immune
response has long been appreciated (reviewed in [126,127]) and
the role of this process in the pathogenesis of a range of autoim-
mune diseases is seen as an increasingly important therapeutic
target [128]. Indeed, we have recently revealed that abatacept
(CTLA-4-Ig) may act by suppression of T cell follicular migration
[129]. At the other end of the scale, the migration of various cell
types around the body and in and out of joints is perceived as cru-
cial to the pathogenesis of RA [130] but remains relatively under-
studied. In both cases, determining the molecules (e.g., chemokines
and integrins) responsible for regulation of migration and localisa-
tion will be the key steps to therapeutic intervention [131].
9. Localisation of pathological consequences
How, why and whether the systemic immune responses initi-
ated and expanded in secondary lymphoid organs are subse-
quently focused on the joints in RA are crucial questions. The
answers may lie in the biomechanics of the joint itself, the relation-
ship between address codes of eliciting and target organ and
whether we consider RA to be a tissue speciﬁc or systemic disease.
Importantly, we need to consider the location and timing of the key
events of the initiation, establishment, maintenance and regulation
of autoimmune responses in RA.
10. Why joints?
The major clinical sign of RA is joint pathology, which manifests
as a symmetric polyarthritis with associated swelling and pain in
multiple joints, often initially in the joints of the hand, wrist and
feet [132]. This is recapitulated in many animal models, however
why the systemic autoimmunity that characterises the preclinical
phase of the disease eventually targets the joints is still unknown.
Interestingly, our own studies using an adoptive transfer model of
arthropathy reveal early involvement of the articular environment
was prerequisite for development of autoreactive responses as
immunisation in other systemic sites did not lead to autoimmune
arthritis (Benson, R.A., unpublished data). Reasons related to the
environment and function of the joint, namely biomechanical
stress, hypoxia, and trauma could potentially explain its preferen-
tial involvement in RA. Joint overuse and misuse in conjunction
with trauma have been linked to the development of osteoarthritis
[133], however their role in RA development is not clear. Interest-
ingly, a case control study links physical trauma with RA onset
[134], whereas in experimental arthritis development of the dis-
ease was associated with joint microbleeding [135]. We could
speculate that local microtrauma or infection leads to inﬂamma-
tion, damage, antigen release and activation of resident DCs, which
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individuals, target the autoimmune response to the joint. In exper-
imental arthritis hypoxia-induced cell death was linked to the
release of DAMPS, such as HMGB1, that perpetuated the inﬂamma-
tory response [136]. Whether local trauma, in the relatively
hypoxic joint environment, can initiate events like these is
unknown, however it would be intriguing to hypothesise that
cell death and sterile damage-related signals dictate tissue
localisation.
11. Limitations to current models
Major contributions to the understanding of RA pathogenesis
have been made using mouse models of disease. These have al-
lowed some of the intricacies of cellular interactions and cytokine
networks to be deciphered that promote inﬂammatory arthropa-
thies. However, some of the most widely used animal models have
important limitations. The contribution of CD4+ T cells to immune
mediated arthritis has clearly been demonstrated in the collagen
induced arthritis model (CIA) [137]. While serum transfer from
CIA mice results in arthritic inﬂammation in susceptible mice
without stimulation of collagen speciﬁc T cells, disease is transient
and mostly does not result in cartilage erosion [138,139]. A colla-
gen-derived peptide, CII 250–270, has already been used in an anti-
gen speciﬁc approach for prevention/treatment of arthritis in CIA
[140]. Oral administration of this peptide suppresses antigen spe-
ciﬁc T cell and antibody responses. Crucially, further characterisa-
tion has revealed that the immunogenic CII peptide 256–270 binds
to I-Aq via the same key anchor residues (positions 263 and 264) as
when binding DR1 and DR4 [141–143]. A recent study has demon-
strated the effectiveness of antigen speciﬁc intervention in CIA uti-
lising this peptide. A monomeric murine recombinant T cell
receptor ligand containing single chain two domain I-Aq molecules
covalently linked to the immunogenic CII peptide reduced clinical
and histological signs of CIA and induced long term tolerance when
given as a prophylactic [144]. The effectiveness of this ingenious
antigen speciﬁc therapy has also been proven in EAE [145,146].
Unfortunately, this does not portray the complexity of human dis-
ease, where spontaneously arising auto-reactive T cells are likely to
be of multiple antigen speciﬁcities. These studies rely on breaching
existing tolerance to a single self-antigen before re-establishing
tolerance to the same antigen. Identiﬁcation of antigen speciﬁcity
in spontaneously arising autoimmune arthritis would be consider-
ably more beneﬁcial in understanding how breach of tolerance is
likely to occur in human RA. Spontaneously arising arthropathy
is seen in the K/BxN mouse [35]. In this model, disease occurs in
the F1 progeny of NOD mice crossed with the KRN TCR transgenic
mouse. In this system the transgenic TCR shows reactivity with
glucose-6-phosphate isomerase (GPI) in the context of I-Ag7. Path-
ogenesis relies on T cell activation of B cells and their production of
complement ﬁxing GPI speciﬁc antibody. A newly described spon-
taneous arthritis model where HA is expressed as a self-antigen
under an MHC class II promoter is driven by HA speciﬁc TCR Tg
CD4 T cells [147]. While both of these models develop arthritis
spontaneously and share many characteristics with human dis-
ease, they both utilise a single speciﬁcity TCR transgenic to initi-
ate/maintain disease. Ideally, multiple T cell antigen speciﬁcities
should be involved in a disease model. Such spontaneously arising
auto-reactive T cell responses are evident in SKG mice [21,148].
Here, a point mutation in the gene encoding the TCR signalling
molecule ZAP-70 results in altered thymic selection. These mice
have high titres of rheumatoid factor, anti-type II collagen, anti-
CCP and heat shock protein reactive antibodies, demonstrating
multiple antigen speciﬁc response. However, the antigens recogni-
sed by T cells remain unknown.Understanding the timing, location and mechanisms of the
‘breach of tolerance’ that we hypothesise leads to RA, will require
the ability to identify and track spontaneously arising arthritogenic
cells in mice and humans. We have developed a novel model of im-
mune mediated arthritis in which stimulation of a trackable, T cell
population with irrelevant antigen speciﬁcity, induces local articu-
lar inﬂammation and leads to spontaneous breach of B and T cell
tolerance [112,149]. This spontaneous breach of self-tolerance is
dependent on conventional dendritic cells [94], can be exacerbated
by depletion of plasmacytoid dendritic cells [96] and does not re-
quire dual, therefore potentially autoreactive, TcR expression by
the inciting transferred T cell population (conﬁrmed by adoptive
transfer of DO11.10 SCID TcR tg T cells which can only express a
single TcR speciﬁc for OVA, Benson, R.A., unpublished data). This
initial phase of inﬂammation is self-resolving over a period of
14 days and represents induction of a preclinical/arthropathy sus-
ceptible phase. Despite minimal evidence for footpad inﬂamma-
tion after this point, autoantibody titres continue to rise, making
mice more susceptible to disease following a second footpad
rechallenge, resembling ﬂares in human disease. This aspect of
the model directly reﬂects human disease in which rheumatoid
factor is detectable long before presentation with clinical symp-
toms. Deciphering the development of pathophysiological T cell re-
sponses in relation to a previous inﬂammatory event also makes
this model particularly relevant to human disease where clinical
presentation and later disease ﬂares are often associated with
infectious events. No peptide sequence homology between ovalbu-
min and type II collagen has been detected but the production of
auto-reactive T cell and antibody responses is both site and antigen
speciﬁc, relying on introduction of the priming antigen (OVA) via
the footpad. The spontaneous nature by which autoreactive T cells
are primed in this model represents a major advantage over ‘‘anti-
gen immunisation’’ models. Additionally, this autoimmune re-
sponse can be studied in the context of a trackable initiating
event, the OVA speciﬁc inﬂammation. Deﬁnition of target antigens
and subsequent construction of recombinant T cell receptor li-
gands will facilitate identiﬁcation/tracking of auto-reactive CD4+
T cells allowing delineation of events leading to their priming
and subsequent disease. Tracking of auto-reactive T cells will en-
able deﬁnition of the immune context in which they are primed.
Once auto-reactive T cells can be identiﬁed, the APCs these clones
interact with can be characterised (which cell type; their activation
state; tissues they have come from and how they acquire antigen),
thus facilitating delineation of the conditions promoting auto-
reactivity.
12. Importance of imaging
Imaging techniques (e.g., PET, SPECT andMRI) have impacted on
arthritis from a diagnostic and assessment of pathology point of
view [150,151]. In contrast, we have emphasised in the preceding
sections the need to perform imaging with cellular resolution. The
most effective approach to acquire this type of data is through
in vivo optical imaging. Optical imaging will allow us to undertake
the important, detailed, kinetic studies of cellular behaviour re-
quired in both lymphoid and disease relevant tissues during initia-
tion, maintenance and resolution/regulation of autoimmunity and
pathology. For clinical assessment and treatment of RA, it is clear
that we must develop imaging modalities that maximise our
spatial resolution within the joint. To this end, the need for high
sensitivity, non-invasive imaging is paramount. With conventional
multiphoton microscopy analysis being limited to a few hundred
nanometres beneath the surface, multiphoton endoscopy (e.g.,
GRIN imaging) allows unparalleled imagingwithin the joint. In con-
junction with this, second harmonic generation (SHG) signals
3646 R.A. Benson et al. / FEBS Letters 585 (2011) 3640–3648produced intrinsically in the body by collagen and elastin ﬁbres in
the joint may be visualised without the need for extrinsic ﬂuoro-
phores. This approach has recently been applied to study morpho-
logical and structural alterations occurring in the joint during the
onset of arthritis in the SKG murine model [152]. Alternatively,
non-invasive approaches with intrinsically deeper imaging poten-
tial include surface enhanced resonance Raman scattering (SERRS)
imagingwhich can detect signal at depths of around 1–2 cm inmice
[153]. Using these microendoscopic approaches have enabled
imaging of human muscle dynamics [154] as well as deep brain
imaging of the effect of tumour growth on gliomas in mice [155].
The relatively small sizes (300–1000 lm) of these lenses, suggests
their potential for future studies of cell or structural ﬂuorescence
in joints.
Future developments are required in technologies such as light
activated probes and drugs, far red ﬂuorophores allowing deeper
tissue imaging, enhancers/modulators of reporter ﬂuorescent pro-
teins, the ability to image and analyse multiple signals and ﬁnally,
but maybe most importantly the ability to analyse the complex
data sets that will be generated.13. Future perspectives
Reductionist approaches have provided a list of cells and mole-
cules involved in autoimmunity. The challenge now is to integrate
this information into a working model of RA pathogenesis (e.g.,
Fig. 1), accounting for temporal and tissue speciﬁc aspects of dis-
ease. Developments in personalised medicine, in terms of earlier
diagnosis, mean that it is now possible to intervene at the earliest
stages of disease to reduce progression to pathology. Continued ad-
vances should mean that we could advance to a stage where the
initial breach of tolerance is prevented. Although this is the ulti-
mate aim, advancing our understanding of breach of tolerance in
spatiotemporal in vivo systems has the additional advantage of
rationalising use of existing therapeutics, i.e., right drug, right time,
right place, right person.
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